BioSyent Inc.
RX
Rank in Stocks
#18141
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops,... BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Share Price
$12.68
Last synced: 2026-11-09
Market Cap
$143.35M
Change (1 day)
1.02%
Change (1 year)
63.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioSyent Inc. (RX)
Category
Healthcare
EPS for BioSyent Inc. (RX)
EPS as of June 2026 TTM: $0.63
According to BioSyent Inc.'s latest financial reports, its current EPS (TTM) is $0.63. At the end of 2025 the company had an EPS of $0.58, an increase over its 2024 EPS of $0.44.
EPS history for BioSyent Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.63 | 8.47% |
| 2025 | $0.58 | 32.78% |
| 2024 | $0.44 | 7.73% |
| 2023 | $0.41 | 25.66% |
| 2022 | $0.32 | -18.02% |
| 2021 | $0.40 | 73.66% |
| 2020 | $0.23 | -4.45% |
| 2019 | $0.24 | -17.08% |
| 2018 | $0.29 | 0.45% |
| 2017 | $0.29 | 28.11% |
| 2016 | $0.22 | 14.80% |
| 2015 | $0.19 | -1.67% |
| 2014 | $0.20 | 50.38% |
| 2013 | $0.13 | 9.03% |
| 2012 | $0.12 | 310.54% |
| 2011 | $0.03 | 635.00% |
| 2010 | 0.00 | -120.10% |
| 2009 | $-0.02 | 5.29% |
| 2008 | $-0.02 | 83.50% |
| 2007 | $-0.01 | -139.77% |
| 2006 | $0.03 | -24.71% |
| 2005 | $0.03 | -307.23% |
| 2004 | $-0.02 | -40.29% |
| 2003 | $-0.03 | 8.17% |
| 2002 | $-0.03 | -145.49% |
| 2001 | $0.06 | -306.96% |
| 2000 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | 168.64% |
US
|
|
| $1.93 | 206.91% |
SE
|
|
| $6.91 | 999.03% |
FR
|
|
| $0.02 | -96.90% |
HK
|
|
| $2.71 | 330.74% |
IT
|
Questions about BioSyent Inc.'s earnings per share (EPS)
What is BioSyent Inc.'s earnings per share (EPS)?
BioSyent Inc.'s earnings per share (EPS) over the last twelve months is $0.63, as of Jun 2026.
What was BioSyent Inc.'s earnings per share (EPS) in 2025?
In 2025, BioSyent Inc.'s earnings per share (EPS) was $0.58, 31.82% more than in 2024 ($0.44).
How has BioSyent Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioSyent Inc.'s earnings per share (EPS) went from $0.23 to $0.58, an average growth of 20.32% a year.
How does BioSyent Inc.'s earnings per share (EPS) compare with similar companies?
BioSyent Inc.'s earnings per share (EPS) ($0.63) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.91.